ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2011
Targeting T cells with bispecific antibodies for cancer therapy.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- The expression of PD-L1 on tumor-derived exosomes enhances infiltration and anti-tumor activity of αCD3 × αPD-L1 bispecific antibody-armed T cells.Cancer immunology, immunotherapy : CII · 2024Article
- Tuning the potency and selectivity of ImmTAC molecules by affinity modulation.Clinical and experimental immunology · 2024Article
- Rigid crosslinking of the CD3 complex leads to superior T cell stimulation.Frontiers in immunology · 2024Article
- Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.Frontiers in immunology · 2023Review
- Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity.Frontiers in immunology · 2023Article
- LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.Oncogene · 2022Article
- B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors.World journal of gastrointestinal oncology · 2021Review
- Photocontrolled activation of small molecule cancer therapeutics.RSC medicinal chemistry · 2020Review
- Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.Cancer research · 2020Article
- Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.Investigational new drugs · 2019Article
- Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.Antibodies (Basel, Switzerland) · 2019Review
- Current progress in innovative engineered antibodies.Protein & cell · 2018Review
- Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.Protein & cell · 2018Article
- Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.Protein science : a publication of the Protein Society · 2017Article
- A New Agent in the Strategy to Cure AIDS.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Article
- Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Cancer immunology research · 2015Article
- Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.Nature biotechnology · 2014Article
- Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.OncoimmunologyArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Bispecific antibodies (BiAbs) offer a unique opportunity to redirect immune effector cells to kill cancer cells. BiAbs combine the benefits of different binding specificities of two monoclonal antibodies (mAbs) into a single construct. This unique feature of BiAbs enables approaches that are not possible with single mAbs. Advances in antibody engineering and antigen profiling of malignant cells have led to the development of a number of BiAb formats and their combinations for redirecting effector cells to tumor targets. There have been significant advances in the design and application of BiAbs for intravenous and local injection.The initial barrier of cytokine storm has been partially overcome by more recent constructs that have improved clinical effectiveness without dose-limiting toxicities. Since the recent revival of BiAbs, there has been multiple, ongoing, phase I/II and III trials, and some promising clinical outcomes have been reported in completed clinical studies. This review focuses on arming T cells with BiAbs to create the 'poor man's cytotoxic lymphocyte'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.